Almac Announces Launch of IXRS®3 Partnership Network
Almac Clinical Technologies, a member of the Almac Group, has announced the launch of its IXRS®3 Partnership Network for biopharmaceutical sponsors, which aims to accelerate the development and delivery of eClinical solutions.
This Partnership Network gives sponsors and CROs the opportunity to share data and solutions to build a more inclusive clinical trial experience for all sites and patients.
Reference
Almac Announces Launch of IXRS®3 Partnership Network. (2023, April 25). Almac.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
